The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection

Acibadem University

Status: Unknown

Conditions: Covid19

Study type: Observational

Funder types: Other

Identifiers

NCT04769245

Acibadem Healthcare Group

Details and patient eligibility

About

Pathogen-free, concentrated, pooled convalescent plasma has higher SARS-CoV2 antibody titers and neutralizing antibody activities, without requiring blood group compatibility that allows patient accessibility in a shorter time and has safe plasma characteristic.

Full description

The efficacy of SARS-CoV2 standard single donor convalescent plasma varied according to the application time and most importantly the amount of antibody that is administered. Single donor plasma has some drawbacks; such as the insufficient levels of neutralizing antibody activities, the requirements of blood group compatibility, and the risk of infection transmission. In this study, the efficacy and safety of pathogen inactivated, isohemagglutinin-depleted (concentrated) and pooled convalescent plasma was investigated.

Enrollment: 40 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Are over the age of 60 or-
• Between the ages of 18-60, serious comorbidities (cancer, COPD, cardiovascular illness, hypertension, DM)
• Clinically diagnose COVID-19 or radiological diagnosed COVID-19 pnemonia

Exclusion criteria

• Multiple Organ Failure

Trial design

40 participants in 2 patient groups

Single donor convalescent plasma

Description:

Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with single donor plasma

ACB- IP 1.0

Description:

Patients who had positive reverse-transcriptase-polymerase-chain-reaction (RT-PCR) for SARS-CoV2 and radiologically confirmed pneumonia treated with ACB- IP 1.0 pathogen-free concentrated cocktail convalescent plasma